- call +1-201-465-4211
- email sales@mrinsights.biz
Publish Date: Jan, 2019|Report ID: 141110|Price: $3480
Nilotinib in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.Scope of the Report:This rep...
Know MorePublish Date: Jan, 2019|Report ID: 141109|Price: $4880
Everolimus is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).Scope of the Report:This report focuses on the Everolimus Drug ...
Know MorePublish Date: Jan, 2019|Report ID: 141108|Price: $3480
Everolimus is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).Scope of the Report:This report focuses on the Everolimus Drug ...
Know MorePublish Date: Jan, 2019|Report ID: 141107|Price: $4880
Everolimus is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).Scope of the Report:This report focuses on the Afinitor Drug in...
Know MorePublish Date: Jan, 2019|Report ID: 141106|Price: $3480
Everolimus is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).Scope of the Report:This report focuses on the Afinitor Drug in...
Know MorePublish Date: Jan, 2019|Report ID: 141105|Price: $4880
Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer.Scope of the Report:This report focuses on the Rituximab Drug in global market, e...
Know MorePublish Date: Jan, 2019|Report ID: 141104|Price: $3480
Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer.Scope of the Report:This report focuses on the Rituximab Drug in global market, e...
Know MorePublish Date: Jan, 2019|Report ID: 141103|Price: $4880
It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysp...
Know MorePublish Date: Jan, 2019|Report ID: 141102|Price: $3480
It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysp...
Know MorePublish Date: Jan, 2019|Report ID: 141099|Price: $4880
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).Scope of the Report:This report focuses on the Sol...
Know More